| ID | 1168 |
| Name of the vaccine | Q-VAX |
| Microbe | Bacteria |
| Disease name | Q Fever |
| Name of bacteria | Coxiella burnetii |
| Type of vaccine | Inactivated |
| Nucleic acid content | Linear DNA |
| Age | 15 years and older (who work in high-risk occupations) |
| Description of the vaccine | Formalin-inactivated phase I Coxiella burnetii vaccine. |
| Name of the manufacturer | Seqirus Pty Ltd |
| Name of the manufacturing country | Australia |
| Year of manufacture | 1999 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative bacterium. |
| Efficacy | 100% protective efficacy. |
| Vaccine formulation | Cloudy colourless liquid |
| Dosage | Single dose of 0.5 mL. |
| Mechanism of action | Early antibody response is predominantly with the IgM subclass, IgG antibodies appear later and cell mediated immunity develops. |
| Route of administration | Subcutaneous |
| Indications | Recommended for people working with cattle, sheep or goats, or products from these animals. |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Redness, itchiness, pain, burning, swelling, headaches, fever, muscle ache, fatigue, nausea, vomiting, diarrhoea and increased sweating. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | Yes (by inhaling dust particles contaminated by infected animals) |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://labeling.seqirus.com/PI/AU/Q-Vax/EN/Q-Vax-Product-Information.pdf |
| Other name | NA |
| Additional Links | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=237&keywords=
|